200 related articles for article (PubMed ID: 6668504)
1. Phase I study of spirogermanium given daily.
Legha SS; Ajani JA; Bodey GP
J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
Budman DR; Schulman P; Vinciguerra V; Degnan TJ
Cancer Treat Rep; 1982 Jan; 66(1):173-5. PubMed ID: 7053254
[TBL] [Abstract][Full Text] [Related]
3. A Phase I trial of spirogermanium administered on a continuous infusion schedule.
Woolley PV; Ahlgren JD; Byrne PJ; Priego VM; Schein PS
Invest New Drugs; 1984; 2(3):305-9. PubMed ID: 6511236
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of spirogermanium in advanced human malignancy.
Vogelzang NJ; Gesme DH; Kennedy BJ
Am J Clin Oncol; 1985 Aug; 8(4):341-4. PubMed ID: 3909806
[TBL] [Abstract][Full Text] [Related]
5. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
[No Abstract] [Full Text] [Related]
6. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
Williamson SK; Slavik M
Invest New Drugs; 1991 Feb; 9(1):49-52. PubMed ID: 2026484
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of spirogermanium in patients with advanced colorectal carcinoma.
Ajani JA; Faintuch JS; McClure RK; Levin B; Boman BM; Krakoff IH
Invest New Drugs; 1986; 4(4):383-5. PubMed ID: 3583645
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
11. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
Slavik M; Blanc O; Davis J
Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of spirogermanium.
Schein PS; Slavik M; Smythe T; Hoth D; Smith F; Macdonald JS; Woolley PV
Cancer Treat Rep; 1980; 64(10-11):1051-6. PubMed ID: 7459890
[TBL] [Abstract][Full Text] [Related]
13. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
14. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Brown TD; Ettinger DS; Donehower RC
J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of oral spirogermanium.
Harvey J; McFadden M; Smith FP; Joubert L; Schein PS
Invest New Drugs; 1990 Feb; 8(1):53-6. PubMed ID: 2345069
[TBL] [Abstract][Full Text] [Related]
17. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of spirogermanium in advanced ovarian carcinoma.
Brenner DE; Jones HW; Rosenshein NB; Forastiere A; Dillon M; Grumbine F; Tipping S; Burnett L; Greco FA; Wiernik PH
Cancer Treat Rep; 1983 Feb; 67(2):193-4. PubMed ID: 6825131
[No Abstract] [Full Text] [Related]
19. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of spirogermanium in patients with advanced malignant lymphoma.
Sessa C; ten Bokkel Huinik W; Clavel M; Lev LM; Joss RA; Renard J; Cavalli F
Invest New Drugs; 1989 Jul; 7(2-3):219-22. PubMed ID: 2793376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
